Xencor has been granted a patent for a method to treat CD20-expressing cancer in humans using a bispecific anti-CD20×anti-CD3 antibody in a flat escalation dosing regimen with at least five phases. The antibody includes specific polypeptides and dose amounts, independent of the patient’s weight, administered every 6-8 days. GlobalData’s report on Xencor gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor's grant share as of May 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Bispecific antibody treatment for cd20-expressing cancer in humans
A recently granted patent (Publication Number: US11987636B2) discloses a method for treating a human subject with a CD20-expressing cancer using a bispecific anti-CD20×anti-CD3 antibody. The method involves administering the antibody in five phases, with varying dose amounts ranging from 0.5 mg to 55 mg, independent of the subject's weight. The time period between each administration is approximately 6 to 8 days. The antibody comprises specific amino acid sequences and binding domains targeting CD3 and CD20. Additionally, the patent includes provisions for a sixth phase of treatment with specific dose amounts and intervals between administrations.
Furthermore, the patent specifies that the CD20-expressing cancer targeted by this method can include various types of lymphomas, such as Non-Hodgkin lymphoma, including B-cell NHL and specific subtypes like Burkitt's lymphoma, follicular lymphoma, and mantle cell lymphoma, among others. The method also involves administering a combination of a corticosteroid, an antihistamine, and acetaminophen before each antibody administration. The patent provides detailed dosage information for each phase of treatment, emphasizing the precise amounts and intervals for optimal therapeutic effect. Overall, the patent outlines a comprehensive and specific approach to treating CD20-expressing cancers, particularly lymphomas, using a bispecific antibody with defined characteristics and administration protocols.
To know more about GlobalData’s detailed insights on Xencor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
